Perspectives on the development of novel potentially active quinolones against tuberculosis and cancer

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 9, 2012, Pages 866-874

  Facchinetti, V ^a,b   Gomes, C R B ^b   de Souza, M V N ^b   Vasconcelos, T R A ^a  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Biological activity; Cancer; Drugs; Quinolones; Tuberculosis

Indexed keywords

6 NITROQUINOLONE; AMIKACIN; ANTINEOPLASTIC AGENT; BCG VACCINE; BENZOTRIAZOLE DERIVATIVE; CAMPTOTHECIN; CAPREOMYCIN; CIPROFLOXACIN; ETHAMBUTOL; EVOCARPINE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; NAPHTHYRIDINE DERIVATIVE; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; RIFAMPICIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; VOSAROXIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL INFECTION; CANCER CELL CULTURE; CONVULSION; COUGHING; DRUG COST; DRUG SYNTHESIS; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FATIGUE; FEVER; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HUMAN; HYBRIDIZATION; IN VITRO STUDY; LUNG TUBERCULOSIS; MORBIDITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NEOPLASM; NIGHT SWEAT; OVARY CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PSYCHOSIS; RESPIRATORY TRACT INFECTION; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS; URINARY TRACT INFECTION; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTITUBERCULAR AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DESIGN; DRUG DISCOVERY; HUMANS; MICE; MICROBIAL VIABILITY; MYCOBACTERIUM TUBERCULOSIS; NEOPLASMS; QUINOLONES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBERCULOSIS, PULMONARY;

EID: 84862834575     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712800959099     Document Type: Article

References (50)

1. Mugnaini, C.; Pasquini, S.; Corelli, F. The 4-quinolone-3-carboxylic acid motif as a multivalent scaffold in medicinal chemistry. Curr. Med. Chem., 2009, 16, 1746-1767.
2. Hadjeri, M.; Peiller, E. L.; Beney, C.; Deka, N.; Lawson, M. A.; Dumontet, C.; Boumendjel, A. Antimitotic activity of 5-hydroxy-7- methoxy-2-phenyl -4-quinolones. J. Med. Chem., 2004, 47, 4964-4970.
3. Dayam, R.; Al-Mawsawi, L. Q.; Zawahir, Z.; Witvrouw, M.; Debyser, Z.; Neamati, N. Quinolone 3-Carboxylic Acid Pharmacophore: Design of Second Generation HIV-1 Integrase Inhibitors. J. Med. Chem., 2008, 51, 1136-1144.
4. Park, C. H.; Lee, J.; Jung, H. Y.; Kim, M. J.; Lim, S. H.; Yeo, H. T.; Choi, E. C.; Yoon, E. J.; Kim, K. W.; Cha, J. H.; Kim, S. H.; Chang, D. J.; Kwon, D. Y.; Lia, F.; Suha, Y. G. Identification, biological activity, and mechanism of the anti-ischemic quinolone analog. Bioorg. Med. Chem., 2007, 15, 6517-6526.
5. Meinke, P. T.; Colletti, S. L.; Doss, G.; Myers, R. W.; Gurnett, A. M.; Dulski, P. M.; Darkin-Rattray, S. J.; Allocco, J. J.; Galuska, S.; Schmatz, D. M.; Wyvratt, M. J.; Fisher, M. H. Synthesis of apicidin-derived quinolone derivatives: parasite-selective histone deacetylase inhibitors and antiproliferative agents. J. Med. Chem., 2000, 43, 4919-4922.
6. Kahnberg, P.; Howard, M. H.; Liljefors, T.; Nielsen, M.; Elsebet, O.; Sterner, O.; Pettersson, I. The use of a pharmacophore model for identification of novel ligands for the benzodiazepine binding site of the GABA receptor. J. Mol. Graph. Model., 2004, 23, 253-261.
7. De Souza, M. V. N.; Vasconcelos, T. R. A.; de Almeida, M. V.; Cardoso, S. H. Fluoro quinolones: an important class of antibiotics against tuberculosis. Curr. Med. Chem. 2006, 13, 455-463.
8. Minoviski, N.; Vracko, M.; Solmajer, T. Quantitative structure-activity relationship study of antitubercular fluoroquinolones. Mol. Divers. 2011, 15, 417-426.
9. Bradbury, B. J.; Pucci, M. J. Recent advances in bacterial topoisomerase inhibitors. Curr. Opin. Pharm. 2008, 8, 574-581.
10. Agência Nacional de Vigilância Sanitária. http://www.anvisa.gov.br (accessed June 12, 2011).
11. Rang, H. P.; Dale, M. M.; Ritter, J. M.; Flower, R. J. Rang and Dale's Pharmacology, Churchill Livingstone, Ed. 2008, chapter 46.
12. Foroumadi, A.; Emami, S.; Rajabalian, S.; Badinloo, M.; Mohammadhosseine, N.; Shafiee, A. N-substituted piperazinyl quinolones as potential cytotoxic agents: structure-activity relationships study. Biomed. Pharmacother., 2009, 63, 216-220.
13. Wentland, M. P.; Lesher, G. Y.; Reuman, M.; Gruett, M. D.; Singh, B.; Aldous, S. C.; Dorff, P. H.; Rake, J. B.; Coughlin, S. A. Mammalian to poisomerase II inhibitory activity of 1-cyclopropyl- 6,8-difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarboxylic acid and related derivatives. J. Med. Chem., 1993, 36, 2801-2809.
14. Gould, R., Jr.; Jacobs, W. A. The synthesis of certain substituted quinolines and 5,6-benzoquinolines. J. Am. Chem. Soc., 1939, 61, 2890-2895.
15. Grohe, R.; Heitzer, H. Cycloaracylation of enamines. I. Synthesis of 4-quinolone-3- carboxylic acids. Liebigs Ann. Chem., 1987, 1, 29-37.
16. Genelot, M.; Bendjeriou, A.; Dufaud, V.; Djakovitch, L. Optimised procedures for the one-pot selective syntheses of indoxyls and 4- quinolones by a carbonylative Sonogashira/cyclisation sequence. Appl. Catal. A: Gen., 2009, 369, 125-132.
17. Genelot, M.; Dufaud, V.; Djakovitch, L. Heterogeneous metalloorganocatalysis for the selective one-pot synthesis of 2-benzylidene-indoxyl and 2-phenyl-4-quinolone. Tetrahedron 2011, 67, 976-981.
18. World Health Organization/Tuberculosis. http://www.who.int/tb/en/ (accessed June 10, 2011).
19. De Souza, M. V. N.; Facchinetti, V.; Cardinot, D.; Gomes, C. R. B. Produtos Naturais com atividade inibitória da Translocase I, uma promissora classe de compostos contra tuberculose. Bol. Latinoam. Caribe Plant. Méd. Aromat. 2010, 9(1), 1-12.
20. De Souza, M.V.N. Tuberculose em pacientes HIV-positivos, um grave problema de saúde pública mundial. Rev. Bras. Farm. 2006, 87, 42-44.
21. Arbex, M. A.; Varella, M. C. L.; de Siqueira, H. R.; de Mello, F. A. F. Drogas antituberculose: Interações medicamentosas, efeitos adversos e utilização em situações especiais. Parte 2: Fármacos de segunda linha. J. Braz. Pneumol. 2010; 36(5), 641-656.
22. Feng, L.; Liu, M.; Zhang, S.; Chai, Y.; Wang, B.; Zhang, Y.; Lv, K.; Guan, Y.; Guo, H.; Xiao, C. ChemInform Abstract: Synthesis and in vitro Antimycobacterial Activity of 8-OCH3 Ciprofloxacin Methylene and Ethylene Isatin Derivatives. Eur. J. Med. Chem. 2011, 46, 341-348.
23. De Souza, M. V. N. A tuberculose e o desenvolvimento de novos tuberculostáticos em Far-Manguinhos (FIOCRUZ) no Rio de Janeiro Rev. Virtual. Quim. 2009, 1(1), 9-16.
24. World Health Organization/Tuberculosis. http://www.who.int.tb/publications/2009/airborne/background/definition/en/ (accessed August 10, 2011).
25. De Souza, M. V. N.; Vasconcelos, T. R. A. Fármacos no combate à tuberculose: passado, presente e futuro. Quím. Nova 2005, 28, 678-682.
26. Takiff, H.; Guerrero. Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob. Agents Chemother. 2011, 55(12), 5421-5429.
27. Ziganshina, L. E.; Squire, S. B. Fluoroquinolones for treating tuberculosis. Cochrane Database of Systematic Reviews 2008, 1, 1-57.
28. De Sarro, A.; De Sarro, G. Adverse reactions to fluoroquinolones. An overview on mechanistic aspects. Curr. Med. Chem. 2001, 8, 371-384.
29. von Rosenstiel, N.; Adam D. Quinolones anti bacterials. An update of their pharmacology and therapeutic use. Drugs., 1994, 47, 872-901.
30. Andersson, M. I.; Macgowan, A. P. Development of the quinolones. J. Antimicrob. Chemother. 2003, 51(S1), 1-11.
31. Senthilkumar, P.; Dinakaran, M.; Yogeeswari, P.; China, A.; Nagaja, V.; Sriram, D. Antimycobacterial activities of novel fluoroquinolones. Biomed. Pharmacotherapy 2009, 63, 27-35.
32. Saraiva, M. F.; de Souza, M. V. N.; Dau, M. E. T. H.; Araújo, D. P.; de Carvalho, G. S. G.; de Almeida, M. V. Synthesis and anti tubercular evaluation of new fluoroquinolone derivatives coupled with carbohydrates. Carb. Res. 2010, 345, 761-767.
33. De Almeida, M. V.; Saraiva, M. F.; de Souza, M. V. N.; da Costa, C. F.; Vicente, F. R. C.; Lourenço, M. C. S. Synthesis and antitubercular activity of lipophilic moxifloxacin and gatifloxacin derivatives. Bioorg. Med. Chem. lett. 2010, 17, 5661-5664.
34. Senthilkumar, P.; Dinakaran, M.; Yogeeswari, P.; Sriram, D.; China, A.; Nagaja, V. ChemInform Abstract: Synthesis and Antimycobacterial Activities of Novel 6-Nitroquinolone-3- carboxylic Acids. Eur. J. Med. Chem. 2009, 44, 345-358.
35. Dinakaran, M.; Senthilkumar, P.; Yogeeswari, P.; China, A.; Nagaja, V.; Sriram, D. Novel of loxacin derivatives: Synthesis, antimycobacterial and toxicological evaluation. Bioorg. Med. Chem. Lett. 2008, 18, 1229-1236.
36. Carta, A.; Palomba, M.; Briguglio I.; Corona, P.; Piras, S.; Jabes, D.; Guglierame, P.; Molicotti, P.; Zanetti, S. Synthesis and antimycobacterial activities of triazoloquinolones. Eur. J. Med. Chem. 2011, 46, 320-326.
37. Wube, A. A.; Hüfner, A.; Thomaschitz C.; Blunder, M.; Kollroser, M.; Bauer, R.; Bucar, F. Design, synthesis and antimycobacterial activities of 1-methyl-2-alkenyl-4(1H)-quinolones. Bioorg. Med. Chem. 2011, 19, 567-579.
38. World Health Organization/Cancer. http://www.who.int/mediacentre/factsheets/fs297/en/index.html (accessed July 20, 2011).
39. Jemal, A.; Bray, F. Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90.
40. Caleta, I.; Kralj, M.; Marjanovic, M.; Bertosa, B.; Tomic, S.; Pavilovic, G.; Pavelic, K.; Karminski-Zamola, G. Novel cyano-and amidinobenzothiazole derivatives: synthesis, antitumor evaluation, and X-ray and quantitative structure-activity relationship (QSAR) analysis. J. Med. Chem., 2009, 52, 1744-1756.
41. Tomita, K.; Tsuzuki, Y.; Shibamori, K. -I.; Tashima, M.; Kajikawa, F.; Sato, Y.; Kashimoto, S.; Chiba, K.; Hino, K. Synthesis and structure-activity relationships of novel 7-substituted 1,4- dihydro- 4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. J. Med. Chem. 2002, 45, 5564-5575.
42. Tsuzuki, Y.; Tomita, K.; Shibamori, K. -I.; Sato, Y.; Kashimoto, S.; Chiba, K. Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine- 3-carboxylic acids as antitumor agents. Part 2. J. Med. Chem. 2004, 47, 2097-2109.
43. Hawtin, R. E.; Stockett, D. E.; Byl, J. A. W.; McDowell, R. S.; Tan, N.; Arkin, M. R.; Conroy, A.; Yang, W.; Osheroff, N.; Fox, J. A. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLosONE. 2010, 5, e10186.
44. Sissi, C.; Palumbo, M. The quinolone family: from antibacterial to anticancer agents. Curr. Med. Chem. Anticancer Agents. 2003, 3, 439-450.
45. Huang, S.; Yang, J.; Tsai, S.; Chen, M.; Hsu, M.; Lin, H.; Chou, L.; Chinag, J.; lee, K.; Huang, L.; Kuo, S. The novel synthesized 2-(3- (methylamino)phenyl)-6-(pyrrolidin-1-yl)quinolin-4-one (Smh- 3)compound induces G2/M phase arrest and mitochondrialdependent apoptotic cell death through inhibition of CDK1 and AKT activity in HL-60 human leukemia cells. Int. J. Oncol. 2011, 38, 1357-1364.
46. You, Q.; Li, Z.; Huang, C.; Yang, Q.; Wang, X.; Guo, Q.; Chen, X.; He, X.; Li, T.; Chern, J. Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modifications. J. Med. Chem. 2009, 52, 5649-5661.
47. Mauser, H.; Guba, W. Recent developments in de novo design and scaffold hopping. Curr. Opin. Drug Discovery Dev. 2008, 11, 365-374.
48. Cragg, G. M.; Grothaus, P. G.; Newman, D. J. Impact of natural products on developing new anti-cancer agents. Chem. Rev. 2009, 109, 3012-3043.
49. Walsby, E. J; Coles, S. J.; Knapper, S.; Burnett, A. K. The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells in synergy with cytarabine. Haematologica. 2011, 96, 393-399.
50. Reis, R. R.; Azevedo, E. C.; de Souza, M. C. B. V.; Ferreira, V. F.; Montenegro, R. C.; Araújo, A. J.; Pessoa, C.; Costa-Lotufo, L. V.; de Moraes, M. O.; Filho, J. D. B. M.; de Souza, A. M. T.; de Carvalho, N. C.; Castro, H. C.; Rodrigues, C. R.; Vasconcelos, T. R. A. Synthesis, anticancer activities and SAR studies of some novel 2-(benzo[d]thiazol-2-yl)-8-substituted-2H-pyrazolo[4,3 c]quinolin-3(5H)-ones. Eur. J. Med. Chem. 2011, 46, 1448-52.